{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=53&q=metastatic+pancreatic", "query": { "q": "metastatic pancreatic", "condition": "Pancreatic Cancer", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 1134, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=54&q=metastatic+pancreatic&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=52&q=metastatic+pancreatic&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T16:35:43.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01251640", "title": "Combination With Gemcitabine in Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "BAY86-9766+Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 90, "start_date": "2011-01-01", "completion_date": "2013-08-01", "has_results": false, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 2, "location_summary": "Aurora, Colorado • Pittsfield, Massachusetts", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Pittsfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01251640" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT05585320", "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Pancreatic Adenocarcinoma", "Malignant Melanoma (Cutaneous)", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "IMM-1-104 Monotherapy (Treatment Group A)", "type": "DRUG" }, { "name": "IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)", "type": "DRUG" }, { "name": "IMM-1-104 + modified FOLFIRINOX (Treatment Group C)", "type": "DRUG" }, { "name": "IMM-1-104 + dabrafenib (Treatment Group D)", "type": "DRUG" }, { "name": "IMM-1-104 + pembrolizumab (Treatment Group E)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 209, "start_date": "2022-10-31", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585320" }, { "nct_id": "NCT00436410", "title": "Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adrenocortical Carcinoma", "Breast Cancer", "Colorectal Cancer", "Gastrointestinal Cancer", "Kidney Cancer", "Liver Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Sarcoma" ], "interventions": [ { "name": "colloidal gold-bound tumor necrosis factor", "type": "BIOLOGICAL" }, { "name": "electron microscopy", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2006-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436410" }, { "nct_id": "NCT03697239", "title": "High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer", "Pancreatic Cancer", "Pancreas Cancer", "Pancreatic Adenocarcinoma Resectable", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Metastasis" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Paclitaxel protein-bound", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hitendra Patel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697239" }, { "nct_id": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Non-small Cell Lung Cancer", "Hepatocellular Carcinoma", "Esophageal Cancer", "Gastric Cancer", "Melanoma", "Renal Cell Carcinoma", "Pancreatic Cancer", "Cervical Cancer", "Triple Negative Breast Cancer", "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Alomfilimab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kymab Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2019-01-28", "completion_date": "2024-10-03", "has_results": true, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 6, "location_summary": "Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829501" }, { "nct_id": "NCT01764477", "title": "Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "PRI-724", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prism Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 5, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764477" }, { "nct_id": "NCT00202800", "title": "Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine, Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health West", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2002-03", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00202800" }, { "nct_id": "NCT05877599", "title": "A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Adenocarcinoma", "Breast Cancer", "Other Solid Tumors", "Ovarian Cancer", "Myeloid Neoplasms (AML/MDS)" ], "interventions": [ { "name": "NT-175", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2023-07-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877599" }, { "nct_id": "NCT00027534", "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Gallbladder Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "TRICOM-CEA(6D)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Michael Morse, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2002-01", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-19T16:35:43.805Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027534" } ] }